Table 1 Numbers of patents in the intent-to-treat (ITT) population and assigned treatment arms in the five contributing studies and the current meta-analysis
Study | FF/VI 200/25 | FF/VI 100/25 | FF/VI 50/25 | VI 25 | FP/SAL 250/50 | SAL 50 | FP 500 | Placebo | Total: ITT ICS treated/non-ICS treated |
|---|---|---|---|---|---|---|---|---|---|
Dransfield et al, 2013 [32] NCT01009463 | 402 | 403 | 408 | 409 | – | – | – | – | 1622 1213/409 |
Dransfield et al, 2013 [32] NCT01017952 | 409 | 403 | 412 | 409 | – | – | – | – | 1633 1224/409 |
NCT00115492 | – | – | – | – | 394 | 403 | – | – | 797 394/403 |
Ferguson et al, 2008 [35] NCT00144911 | – | – | – | – | 394 | 388 | – | – | 782 394/388 |
Crim et al, 2009 [12] NCT00268216 | – | – | – | – | 1533 | 1521 | 1534 | 1524 | 6112 3067/3045 |
Pooled analysis | 811 | 806 | 820 | 818 | 2321 | 2312 | 1534 | 1524 | 10,946 6292/4654 |